Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Castle Biosciences, Inc. (CSTL) vs Myriad Genetics, Inc. (MYGN)

Castle Biosciences, Inc. and Myriad Genetics, Inc. are both Diagnostics & Research companies. Castle Biosciences, Inc. is the larger, with a market value of $1.1B against $396.0M — 2.7× the size. Castle Biosciences, Inc. grew revenue faster over the last twelve months: 3.18% against −3.16%. Castle Biosciences, Inc. has the higher net margin (−5.43% vs −14.0%) and the higher return on invested capital (−9.40% vs −19.9%). Across the 18 metrics below, Castle Biosciences, Inc. leads on 13 and Myriad Genetics, Inc. on 5.

Valuation

Metric CSTL MYGN Diagnostics & Research median
P/E n/m n/m 33.95
P/S 3.03 0.49 4.87
P/B 2.30 1.30 3.12
Price to free cash flow n/m n/m 34.02
EV/EBITDA n/m n/m 25.20
EV/Sales 2.31 0.57 5.66
Earnings yield (1.85%) (28.54%) (1.75%)
Free cash flow yield (0.04%) (3.59%) (0.13%)

Profitability

Metric CSTL MYGN Diagnostics & Research median
Gross margin 77.26% 68.83% 50.89%
Operating margin (8.99%) (12.22%) (8.57%)
Net margin (5.43%) (13.96%) (6.37%)
Free cash flow margin (0.13%) (1.76%) 0.00%
Return on equity (4.20%) (32.54%) (2.92%)
Return on assets (3.51%) (17.11%) (6.71%)
Return on invested capital (9.40%) (19.92%) 0.00%

Growth

Metric CSTL MYGN Diagnostics & Research median
Revenue growth (TTM) 3.18% (3.16%) 7.69%
EPS growth (last fiscal year) (233.87%) (180.14%) —
Revenue growth, 5-year CAGR 40.60% 3.61% 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CSTL MYGN Diagnostics & Research median
Debt to equity 0.02 0.40 0.11
Current ratio 6.04 2.21 2.02
Net debt to EBITDA 46.20 2.11 0.78

Dividend

Metric CSTL MYGN Diagnostics & Research median
Dividend yield — — 0.70%
Payout ratio 0.00 0.00 0.00

Size

Metric CSTL MYGN Diagnostics & Research median
Market cap 1.08b 395.99m 2.56b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack